Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.57 |
| ▸ | HTR3A | P46098 | 11/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | NCF1 | P14598 | 2/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892741 | 0.79 | HTR1A (0.70) | HTR1AHTR3AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29559927 | 0.79 | HTR1A (0.70) | HTR1AHTR3AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5919531 | 0.78 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3428277 | 0.76 | HTR1A (0.70) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9114338 | 0.75 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2NCF1HTR6 | |
| SCHEMBL20994075 | 0.75 | HTR1A (0.52) | HTR1AHTR3AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3801245 | 0.74 | GAA (0.65) | ALDH1A1LMNASMN1; SMN2NCF1RAB9A | |
| SCHEMBL3436305 | 0.74 | ALDH1A1 (0.76) | ALDH1A1NCF1 | |
| SCHEMBL9565829 | 0.74 | AKR1C3 (0.62) | ALDH1A1SMN1; SMN2NCF1RAB9A | |
| SCHEMBL7519963 | 0.74 | CKS1B (0.46) | ALDH1A1LMNASMN1; SMN2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708280-B2 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| US-20160137620-A1 | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors | H. LUNDBECK A/S (DK) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137620-A1 | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors | TPH1, HTR5A, HTR2C | HTR1A 5/4885HTR3A 9/4885ALDH1A1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.